Pre-money venture valuation: How to reach a fair agreement?

Edition

Pre-money venture valuation: How to reach a fair agreement?

There is usually a big disparity between investors and entrepreneurs regarding the valuation of an early-stage biotech company. How to determine what a company is actually worth? How do funds price the assets? What are the biases from each side? What are the points of negotiation?

Sharon Cunningham

CEO
Ireland
Shorla Pharma

Robert Tansley

Partner
United Kingdom
Cambridge Innovation Capital

Eliott Harfouche

Managing Partner
Switzerland
Nodes Advisors

Arnaud Autret

Investment Principal
The Netherlands
M Ventures

Ivan Burkov

Senior Associate, Healthcare Team
The Netherlands
INKEF Capital
  • No products in the cart.